Polarity-sensitive nanocarrier for oral delivery of Sb(V) and treatment of cutaneous leishmaniasis

Polarity-sensitive nanocarrier for oral delivery of Sb(V) and treatment of cutaneous leishmaniasis

Juliane S Lanza,1 Flaviana R Fernandes,1 José D Corrêa-Júnior,2 José MC Vilela,3 Rogério Magalhães-Paniago,4 Lucas AM Ferreira,5 Margareth S Andrade,3 Cynthia Demicheli,6 Maria N Melo,7 Frédéric Frézard...

Full description

Bibliographic Details
Main Authors:	Lanza JS, Fernandes FR, Corrêa-Júnior JD, Vilela JMC, Magalhães-Paniago R, Ferreira LAM, Andrade MS, Demicheli C, Melo MN, Frézard F
Format:	Article
Language:	English
Published:	Dove Medical Press 2016-05-01
Series:	International Journal of Nanomedicine
Subjects:	Propylene glycol antimony leishmaniasis oral amphiphilic complex SAXS.
Online Access:	https://www.dovepress.com/polarity-sensitive-nanocarrier-for-oral-delivery-of-sbv-and-treatment--peer-reviewed-article-IJN

Similar Items

High and low doses of antimony (Sb v) in American cutaneous leishmaniasis: a five years follow-up study of 15 patients
by: MP Oliveira-Neto, et al.
Published: (1996-04-01)

Pentavalent Antimonials: New Perspectives for Old Drugs
by: Raul R. Ribeiro, et al.
Published: (2009-06-01)

COMPARISON OF ORAL CHLOROQUINE WITH SYSTEMIC MEGLUMINE ANTIMONIATE IN TREATMENT OF CUTANEOUS LEISHMANIASIS
by: Muhammad Farooq, et al.
Published: (2021-02-01)

A Case of Cutaneous Leishmaniasis Treated with Hyperbaric Oxygen Therapy
by: Olszański Romuald, et al.
Published: (2016-12-01)

Pharmacometabolomics of Meglumine Antimoniate in Patients With Cutaneous Leishmaniasis
by: Deninson Alejandro Vargas, et al.
Published: (2019-06-01)

Antimonial treatment failure rate in patients with cutaneous leishmaniasis
by: Fariba Jaffary, et al.
Published: (2018-06-01)

Efficacy of intralesional amphotericin B for the treatment of cutaneous leishmaniasis
by: Vahid Mashayekhi Goyonlo, et al.
Published: (2014-01-01)

Drug resistance in leishmaniasis
by: Jaya Chakravarty, et al.
Published: (2010-01-01)

Alginates modification and the prospective uses of their products.
by: Subaryono Subaryono
Published: (2014-03-01)

Novel methods for the encapsulation of meglumine antimoniate into liposomes
by: F. Frézard, et al.
Published: (2000-07-01)

A retrospective cohort study of the effectiveness and adverse events of intralesional pentavalent antimonials in the treatment of cutaneous leishmaniasis
by: Bruna Côrtes Rodrigues, et al.
Published: (2020-12-01)

Pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome-encapsulated meglumine antimoniate
by: D.A. Schettini, et al.
Published: (2005-12-01)

ELECTROCARDIOGRAPHIC CHANGES WITH STANDARD DOSE OF MEGLUMINE ANTIMONIATE THERAPY IN CUTANEOUS LEISHMANIASIS
by: Moizza Tahir, et al.
Published: (2021-08-01)

Standardization of intralesional meglumine antimoniate treatment for cutaneous leishmaniasis
by: Maria Cristina de Oliveira Duque, et al.

Molecular Analysis of Aquaglyceroporin 1 Gene in Non-Healing Clinical Isolates Obtained from Patients with Cutaneous Leishmaniasis from Central of Iran
by: Yasaman Alijani, et al.
Published: (2019-05-01)

Successful treatment of cutaneous leishmaniasis with intralesional meglumine antimoniate: A case series
by: Margarita Arboleda, et al.
Published: (2019-05-01)

RESOLUTION OF CUTANEOUS LEISHMANIASIS AFTER ACUTE ECZEMA DUE TO INTRALESIONAL MEGLUMINE ANTIMONIATE
by: Erica de Camargo Ferreira e Vasconcellos, et al.
Published: (2014-07-01)

Mixed Antimony(V) Complexes with Different Sugars to Modulate the Oral Bioavailability of Pentavalent Antimonial Drugs
by: Weverson A. Ferreira, et al.
Published: (2014-04-01)

Efficacy of Spironolactone Treatment in Murine Models of Cutaneous and Visceral Leishmaniasis
by: Valter Viana Andrade-Neto, et al.
Published: (2021-04-01)

Intralesional treatment with meglumine antimoniate in three patients with New World cutaneous leishmaniasis and large periarticular lesions with comorbidities
by: Maria Inês Fernandes Pimentel, et al.

The effect of Nd:YAG laser therapy on cutaneous leishmaniasis compared to intralesional meglumine antimoniate
by: Mohammad Omidian, et al.
Published: (2019-02-01)

The Additive Effect of Topical Ciprofloxacin 2% on Intralesional Glucantime Injection in Treatment of Cutaneous Leishmaniasis
by: Mohamadjavad Yazdanpanah, et al.
Published: (2020-06-01)

Tratamento da Leishmaniose Tegumentar Americana Treatment of american cutaneous leishmaniasis
by: Edson Borges de Lima, et al.
Published: (2007-04-01)

Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis.
by: López Liliana, et al.
Published: (2012-05-01)

FACTORS ASSOCIATED TO ADHERENCE TO DIFFERENT TREATMENT SCHEMES WITH MEGLUMINE ANTIMONIATE IN A CLINICAL TRIAL FOR CUTANEOUS LEISHMANIASIS
by: Madelon Novato Ribeiro, et al.
Published: (2014-07-01)

Failure of both azithromycin and antimony to treat cutaneous leishmaniasis in Manaus, AM, Brazil Falha da azitromicina e do antimonial no tratamento da leishmaniose cutânea em Manaus, AM, Brasil
by: Alan César Teixeira, et al.
Published: (2008-06-01)

A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omiprazole in the treatment of cutaneous leishmaniasis
by: M.A. Nilforoushzadeh, et al.
Published: (2008-11-01)

Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis: a retrospective review of a Brazilian referral centre
by: Rosiana Estéfane da Silva, et al.
Published: (2016-08-01)

Towards a standard protocol for antimony intralesional infiltration technique for cutaneous leishmaniasis treatment
by: Rosiana Estéfane da Silva, et al.

Distribution of liposome-encapsulated antimony in dogs
by: D.A. Schettini, et al.
Published: (2003-02-01)

Meglumine antimoniate intralesional infiltration for localised cutaneous leishmaniasis: a single arm, open label, phase II clinical trial
by: Dario Brock Ramalho, et al.
Published: (2018-06-01)

Comprehensive economic evaluation of thermotherapy for the treatment of cutaneous leishmaniasis in Colombia
by: Jaiberth Antonio Cardona-Arias, et al.
Published: (2018-01-01)

PANCREATIC TOXICITY AS AN ADVERSE EFFECT INDUCED BY MEGLUMINE ANTIMONIATE THERAPY IN A CLINICAL TRIAL FOR CUTANEOUS LEISHMANIASIS
by: Marcelo Rosandiski LYRA, et al.

Treatment strategies for mucocutaneous leishmaniasis
by: Emilio Palumbo
Published: (2010-01-01)

Low efficacy of azithromycin to treat cutaneous leishmaniasis in Manaus, AM, Brazil Azitromicina para tratamento de leishmaniose cutânea em Manaus, AM, Brasil
by: Alan César Teixeira, et al.
Published: (2007-08-01)

Varicella zoster virus reactivation during or immediately following treatment of tegumentary leishmaniasis with antimony compounds
by: Andrea Barbieri Barros, et al.
Published: (2014-07-01)

Predictors of an unsatisfactory response to pentavalent antimony in the treatment of American visceral leishmaniasis
by: Santos Mácia A., et al.
Published: (2002-01-01)

In Vitro Reduced Susceptibility to Pentavalent Antimonials of a <i>Leishmania infantum</i> Isolate from a Human Cutaneous Leishmaniasis Case in Central Italy
by: Aurora Diotallevi, et al.
Published: (2021-05-01)

Treatment of visceral leishmaniasis
by: E M Moore, et al.
Published: (2010-01-01)

Nutritional status in patients with cutaneous leishmaniasis and a study of the effects of zinc supplementation together with antimony treatment
by: Miguel Guzman-Rivero, et al.
Published: (2014-11-01)

Cannot write session to /tmp/vufind_sessions/sess_7p43nau7e60jqmm0pjvn5ejfnp